Searched for: author%3A%22Pieterman%2C+E.J.%22
(21 - 30 of 30)

Pages

document
van den Hoek, A.M. (author), van der Hoorn, J.W.A. (author), Maas, A.C. (author), van den Hoogen, R.M. (author), van Nieuwkoop, A. (author), Droog, S. (author), Offerman, E.H. (author), Pieterman, E.J. (author), Havekes, L.M. (author), Princen, H.M.G. (author)
Aims: This study aimed to investigate systematically (i) the appropriate dietary conditions to induce the features of the MetS in APOE*3Leiden.humanCholesteryl Ester Transfer Protein (E3L.CETP) mice and (ii) whether the response of this model to different antidiabetic and hypolipidemic drugs is similar as in humans. Methods: Male obese, IR and...
article 2014
document
Ason, B. (author), van der Hoorn, J.W.A. (author), Chan, J. (author), Lee, E. (author), Pieterman, E.J. (author), Nguyen, K.K. (author), Di, M. (author), Shetterly, S. (author), Tang, J. (author), Yeh, W.C. (author), Schwarz, M. (author), Jukema, J.W. (author), Scott, R. (author), Wasserman, S.M. (author), Princen, H.M.G. (author), Jackson, S. (author)
LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance. The therapeutic potential for PCSK9 inhibitors is highlighted by the fact that PCSK9 loss-of-function carriers exhibit 15-30% lower circulating LDL-C and a disproportionately lower...
article 2014
document
Kühnast, S. (author), van der Hoorn, J.W.A. (author), Pieterman, E.J. (author), van den Hoek, A.M. (author), Sasiela, W.J. (author), Gusarova, V. (author), Peyman, A. (author), Schäfer, H.L. (author), Schwahn, U. (author), Jukema, J.W. (author), Princen, H.M.G. (author)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of alirocumab in APOE∗3Leiden. CETP mice. Mice received a Western-type diet and were treated with...
article 2014
document
Gierman, L.M. (author), Kühnast, S. (author), Koudijs, A. (author), Pieterman, E.J. (author), Kloppenburg, M. (author), van Osch, G.J.V.M. (author), Stojanovic-Susulic, V. (author), Huizinga, T.W.J. (author), Princen, H.M.G. (author), Zuurmond. A.M., (author)
Objective Hypercholesterolaemia, a risk factor for atherosclerosis (ATH), has been suggested to have a role in the development of osteoarthritis (OA). To test this hypothesis, the effect of cholesterol and different cholesterol-lowering treatments on OA was investigated in a mouse model resembling human lipoprotein metabolism. Methods Female...
article 2014
document
Sugimoto-Kawabata, K. (author), Shimada, H. (author), Sakai, K. (author), Suzuki, K. (author), Kelder, T. (author), Pieterman, E.J. (author), Cohen, L.H. (author), Havekes, L.M. (author), Princen, H.M. (author), van den Hoek, A.M. (author)
Bile acid sequestrants (BASs) are cholesterollowering drugs that also affect hyperglycemia. The mechanism by which BASs exert these and other metabolic effects beyond cholesterol lowering remains poorly understood. The present study aimed to investigate the effects of a BAS, colestilan, on body weight, energy expenditure, and glucose and lipid...
article 2013
document
Kühnast, S. (author), Louwe, M.C. (author), Heemskerk, M.M. (author), Pieterman, E.J. (author), van Klinken, J.B. (author), van den Berg, S.A.A. (author), Smit, J.W.A. (author), Havekes, L.M. (author), Rensen, P.C.N. (author), van der Hoorn, J.W.A. (author), Princen, H.M.G. (author), Jukema, J.W. (author)
Objective:Niacin potently lowers triglycerides, mildly decreases LDL-cholesterol, and largely increases HDL-cholesterol. Despite evidence for an atheroprotective effect of niacin from previous small clinical studies, the large outcome trials, AIM-HIGH and HPS2-THRIVE did not reveal additional beneficial effects of niacin (alone or in combination...
article 2013
document
Bijland, S. (author), Rensen, P.C.N. (author), Pieterman, E.J. (author), Maas, A.C.E. (author), van der Hoorn, J.W. (author), van Erk, M.J. (author), Havekes, L.M. (author), van Dijk, K.W. (author), Chang, S.C. (author), Ehresman, D.J. (author), Butenhoff, J.L. (author), Princen, H.M.G. (author)
Perfluorobutane sulfonate (PFBS), perfluorohexane sulfonate (PFHxS), and perfluorooctane sulfonate (PFOS) are stable perfluoroalkyl sulfonate (PFAS) surfactants, and PFHxS and PFOS are frequently detected in human biomonitoring studies. Some epidemiological studies have shown modest positive correlations of serum PFOS with non-high-density...
article 2011
document
Scully, M.S. (author), Ort, T.A. (author), James, I.E. (author), Bugelski, P.J. (author), Makropoulos, D.A. (author), Deutsch, H.A. (author), Pieterman, E.J. (author), van den Hoek, A.M. (author), Havekes, L.M. (author), Dubell, W.H. (author), Wertheimer, J.D. (author), Picha, K.M. (author)
Patients treated with recombinant human Epo demonstrate an improvement in insulin sensitivity. We aimed to investigate whether CNTO 530, a novel Epo receptor agonist, could affect glucose tolerance and insulin sensitivity. A single administration of CNTO 530 significantly and dose-dependently reduced the area under the curve in a glucose...
article 2011
document
TNO Kwaliteit van Leven (author), Bijland, S. (author), Pieterman, E.J. (author), Maas, A.C.E. (author), van der Hoorn, J.W.A. (author), van Erk, M.J. (author), van Klinken, J.B. (author), Havekes, L.M. (author), van Dijk, K.W. (author), Princen, H.M.G. (author), Rensen, P.C.N. (author)
The peroxisome proliferator-activated receptor alpha (PPARalpha) activator fenofibrate efficiently decreases plasma triglycerides (TG), which is generally attributed to enhanced very low density lipoprotein (VLDL)-TG clearance and decreased VLDL-TG production. However, because data on the effect of fenofibrate on VLDL production are...
article 2010
document
van der Laan, W.H. (author), Quax, P.H.A. (author), Seemayer, C.A. (author), Huisman, L.G.M. (author), Pieterman, E.J. (author), Grimbergen, J.M. (author), Verheijen, J.H. (author), Breedveld, F.C. (author), Gay, R.E. (author), Gay, S. (author), Huizinga, T.W.J. (author), Pap, T. (author), Gaubius Instituut TNO (author)
Matrix metalloproteinases (MMPs) are believed to be pivotal enzymes in the invasion of articular cartilage by synovial tissue in rheumatoid arthritis (RA). Here, we investigated the effects of gene transfer of tissue inhibitors of metalloproteinases (TIMPs) on the invasiveness of RA synovial fibroblasts (RASF) in vitro and in vivo. Adenoviral...
article 2003
Searched for: author%3A%22Pieterman%2C+E.J.%22
(21 - 30 of 30)

Pages